

## Comparison of survivorship of cementless constructs in primary THA<sup>1</sup>

National Joint Registry for England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey: 21st Annual Report Hips, 2024: 1–182.

Available at: [NJR 21st Annual Report Hips 2024](https://www.njr.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%202024_Hips.pdf)  

### Overview

- The UK National Joint Registry (NJR) reported on primary THA between 1 April 2003 and 31 December 2023, with a follow-up at maximum of 20 years
- Cementless THA accounted for 37% of all primary THA (n=1,561,640)
- Top five most implanted cementless THA prostheses were included in this analysis

### Acknowledgments

We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the HQIP who do not vouch for how the information is presented.

### Results



**98.11%**  
survivorship with  
POLARSTEM®/R3<sup>♦</sup>

**55%**



Lower revision risk  
with POLARSTEM/R3  
compared to class average  
for cementless hip  
combinations at 10 years

#### ODEP<sup>2</sup>

10A\* POLARSTEM  
Cementless Stem  
13A\* R3 HA Cementless Cup  
7A R3 non-HA Cementless Cup




Figure. Cumulative revision of top five most implanted cementless THA prostheses

### Conclusions

POLARSTEM with R3 was associated with a 1.89% revision rate at 10 years. This revision rate corresponds to a 55% reduction in revision risk compared with the class average revision rate for cementless constructs in the NJR.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

#### References:

1. National Joint Registry for England, Wales, and Northern Ireland: 21st Annual Report Hips. Available at: [https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%202024\\_Hips.pdf](https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%202024_Hips.pdf). Accessed January 06, 2025. 2. Orthopaedic Data Evaluation Panel (ODEP). Available at: <http://www.odep.org.uk>. Accessed January 06, 2025.  
Smith & Nephew, Inc. 1450 Brooks Road, Memphis, TN 38116, USA.  
38144 V3 02/25. Published February 2025. ©2025 Smith+Nephew. All rights reserved. ♦Trademark of Smith+Nephew.  
Smith & Nephew Orthopaedics AG, Theilerstrasse 1A, 6300 Zug, Switzerland is the legal manufacturer for POLARSTEM. All Trademarks acknowledged.

Developed by Evidence Communications,  
Global Clinical & Medical Affairs  
[www.smith-nephew.com](http://www.smith-nephew.com)